Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, subject-and Investigator Blinded, Placebo-controlled, Active Comparator, Parallel-group Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Patients With Treatment-resistant Depression

Trial Profile

A Multi-center, Randomized, subject-and Investigator Blinded, Placebo-controlled, Active Comparator, Parallel-group Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Patients With Treatment-resistant Depression

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MIJ 821 (Primary) ; Ketamine
  • Indications Depression; Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 23 May 2019 According to a Cadent Therapeutics media release, the company announced the receipt of the second milestone payment from Novartis following the initiation of this trial.Cadent Therapeutics exclusively licensed the intellectual property for compounds that selectively modulate NR2B-containing NMDA receptors to Novartis. This license included MIJ821 (CAD-9271).Novartis is conducting all research and development for the program.
    • 06 Mar 2019 Planned End Date changed from 10 Mar 2020 to 13 Mar 2020.
    • 06 Mar 2019 Planned primary completion date changed from 10 Mar 2020 to 13 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top